CNS Drugs

, Volume 16, Issue 8, pp 549–562

Newer Antiepileptic Drugs in Bipolar Disorder

Rationale for Use and Role in Therapy
Review Article

Abstract

Antiepileptic drugs (AEDS) are used regularly in the treatment of patients with bipolar disorders. Carbamazepine and valproic acid (sodium valproate) are effective as antimanic treatments, and the success of these medications has prompted investigation of other AEDs as possible treatments in patients with mood disorders.

Lamotrigine appears to be the most promising of the newer AEDs with respect to effects in mood disorders. Current evidence suggests efficacy of this drug both as monotherapy and as an adjunctive agent in bipolar depression, and studies are underway to clarify its efficacy in mood stabilisation and rapid cycling, as currently available data are equivocal. Use of gabapentin is not as well supported in the literature, although data from open trials using it as an adjunctive agent suggest that it may be helpful in patients with bipolar depression. There have been some open trials and case reports supporting the use of topiramate as an adjunctive agent for the treatment of mania; however, data from controlled trials are not yet available.

Further controlled trials of lamotrigine, gabapentin or topiramate as mono-therapy and adjunctive treatment are needed to clarify their potential roles in the treatment of patients with mood disorders.

References

  1. 1.
    Ballenger JC, Post RM. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol 1978; 2(2): 159–75PubMedGoogle Scholar
  2. 2.
    Weiss SRB, Post RM. Kindling: separate vs shared mechanisms in affective disorders and epilepsy. Neuropsychobiology 1998; 38: 167–80PubMedCrossRefGoogle Scholar
  3. 3.
    Bowden C. New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine. Neuropsycho-pharmacology 1998; 19(3): 194–9CrossRefGoogle Scholar
  4. 4.
    Geddes J, Goodwin G. Bipolar disorder: clinical uncertainty, evidence-based medicine and large-scale randomized trials. Br J Psychiatry 2001; 178Suppl. 41: S191–4PubMedCrossRefGoogle Scholar
  5. 5.
    Sachs GS, Printz DJ, Kahn DA, et al. Expert consensus guidelines series: medication treatment of bipolar disorder 2000. Postgrad Med 2000 Apr; Spec No: 1–104Google Scholar
  6. 6.
    Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-noncomparative 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000 May; 57(5): 481–9PubMedCrossRefGoogle Scholar
  7. 7.
    Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999 Jul; 156(7): 1019–23PubMedGoogle Scholar
  8. 8.
    Bowden CL. Predictors of response to divalproex and lithium. J Clin Psychiatry 1995; 56Suppl. 3: 25–30PubMedGoogle Scholar
  9. 9.
    Swann AC, Bowden CL, Morris D, et al. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 1997 Jan; 54: 37–42PubMedCrossRefGoogle Scholar
  10. 10.
    Canadian Pharmacists Association. Compendium of pharma-ceuticals and specialties. 35th ed. Ottawa (ON): Canadian Pharmacists Association, 2000Google Scholar
  11. 11.
    Ketter TA, Frye MA, Corá-Locatelli G, et al. Metabolism and excretion of mood stabilizers and new anti-convulsants. Cell Mol Neurobiol 1999; 19(4): 511–32PubMedCrossRefGoogle Scholar
  12. 12.
    Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder [letter]. Am J Psychiatry 1996 Sep; 153(9): 1236PubMedGoogle Scholar
  13. 13.
    Calabrese JR, Gajwani P. Lamotrigine and clozapine for bipolar disorder [letter]. Am J Psychiatry 2000 Sep; 157(9): 1523PubMedCrossRefGoogle Scholar
  14. 14.
    Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999 Feb; 60(2): 79–88PubMedCrossRefGoogle Scholar
  15. 15.
    Fatemi SH, Rapport DJ, Calabrese JR, et al. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997 Dec; 58(12): 522–7PubMedCrossRefGoogle Scholar
  16. 16.
    Bowden CL, Calabrese JR, McElroy SL, et al. The efficacy of lamotrigine in rapid-cycling and non-rapid-cycling patients with bipolar disorder. Biol Psychiatry 1999; 45: 953–8PubMedCrossRefGoogle Scholar
  17. 17.
    GlaxoSmithKline. Lamictal® (lamotrigine) product monograph. Research Triangle Park (NC): GlaxoSmithKline, 2001 MayGoogle Scholar
  18. 18.
    Erfurth A, Amann B, Grunze H. Female genital disorder as adverse symptom of lamotrigine treatment. Neuropsychobiology 1998; 38: 200–1PubMedCrossRefGoogle Scholar
  19. 19.
    GlaxoSmithKline. Dermatologic effects of Lamictal® (lamotrigine) REV0102. Research Triangle Park (NC): GlaxoSmithKline, 2001. (Data on file)Google Scholar
  20. 20.
    Post RM, Denicoff KD, Frye MA, et al. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology 1998; 38(3): 152–66PubMedCrossRefGoogle Scholar
  21. 21.
    Calabrese JR, Gajwani P. Lamotrigine and clozapine for bipolar disorder [letter]. Am J Psychiatry 2000 Sep; 157(9): 1523PubMedCrossRefGoogle Scholar
  22. 22.
    Labbate LA, Rubey RN. Lamotrigine for treatment refractory bipolar disorder [letter]. Am J Psychiatry 1997 Sep; 154(9): 1317PubMedGoogle Scholar
  23. 23.
    Waiden J, Hesslinger B, van Calker D, et al. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 1996; 29: 193–5CrossRefGoogle Scholar
  24. 24.
    Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997; 17(3): 185–9PubMedCrossRefGoogle Scholar
  25. 25.
    Erfurth A, Waiden J, Grunze H. Lamotrigine in the treatment of schizoaffective disorder. Neuropsychobiology 1998; 38: 204–5PubMedCrossRefGoogle Scholar
  26. 26.
    Erfurth A, Grunze H. New perspectives in the treatment of acute mania: a single case report. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 1053–9PubMedCrossRefGoogle Scholar
  27. 27.
    Kotier M, Matar MA. Lamotrigine in the treatment of resistant bipolar disorder. Clin Neuropharmacol 1998; 21(1): 65–7Google Scholar
  28. 28.
    Kusumakar V, Yatham LN. Lamotrigine treatment of rapid cycling bipolar disorder. Am J Psychiatry 1997 Aug; 154(8): 1171–2PubMedGoogle Scholar
  29. 29.
    Suppes T, Brown ES, McElroy SL, et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 1999; 53: 95–8PubMedCrossRefGoogle Scholar
  30. 30.
    Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997; 72: 145–8PubMedCrossRefGoogle Scholar
  31. 31.
    Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000 Dec; 20(6): 607–14PubMedCrossRefGoogle Scholar
  32. 32.
    Bowden CI, Mitchell P, Suppes T. Lamotrigine in the treatment of bipolar depression. Eur Neuropsychopharmacol 1999; 9Suppl. 4: S113–7PubMedCrossRefGoogle Scholar
  33. 33.
    Preda A, Fazeli A, McKay BG, et al. Lamotrigine as prophylaxis against steroid-induced mania. J Clin Psychiatry 1999; 60(10): 708–9PubMedCrossRefGoogle Scholar
  34. 34.
    Fogelson DL, Sternbach H. Lamotrigine treatment of refractory bipolar disorder. J Clin Psychiatry 1997 Jun; 58(6): 271–3PubMedCrossRefGoogle Scholar
  35. 35.
    Berk M. Lamotrigine and the treatment of mania in bipolar disorder. Eur Neuropsychopharmacol 1999; 9Suppl. 4: S119–23PubMedCrossRefGoogle Scholar
  36. 36.
    Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: a double blind randomized control trial. Ann Clin Psychiatry 2000; 12(1): 5–10PubMedGoogle Scholar
  37. 37.
    Anand A, Oren DA, Berman RM, et al. Lamotrigine treatment of lithium failure outpatient mania — a double blind, placebo-controlled trial [abstract]. In: Soares JC, Gershon S, editors. Bipolar disorders. Third International Conference on Bipolar Disorder; 1999 Jun 17–19; Pittsburg (PA)Google Scholar
  38. 38.
    Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000 Dec; 61(11): 841–50PubMedCrossRefGoogle Scholar
  39. 39.
    Frye MA, Kimbrell TA, Dunn RT, et al. Gabapentin does not alter single-dose lithium pharmacokinetics. J Clin Psychopharmacol 1998; 18(6): 461–4PubMedCrossRefGoogle Scholar
  40. 40.
    Short C, Cooke L. Hypomania induced by gabapentin [letter]. Br J Psychiatry 1995; 166: 679–80PubMedCrossRefGoogle Scholar
  41. 41.
    Leweke FM, Bauer J, Elger CE. Manic episode due to gabapentin treatment [letter]. Br J Psychiatry 1995 May; 166(5): 679–80Google Scholar
  42. 42.
    Hauck A, Bhaumik S. Hypomania induced by gabapentin [letter]. Br J Psychiatry 1995; 167: 549PubMedCrossRefGoogle Scholar
  43. 43.
    Frye MA, Luckenbaugh D, Kimbrell TA, et al. Possible gabapentin-induced thyroiditis [letter]. J Clin Psychopharmacol 1999 Feb; 19(1): 94–5PubMedCrossRefGoogle Scholar
  44. 44.
    Grunze H, Dittert S, Bungert M, et al. Renal impairment as a possible side effect of gabapentin: a single case report. Neuropsychobiology 1998; 38: 198–9PubMedCrossRefGoogle Scholar
  45. 45.
    Labbate LA, Rubey RN. Gabapentin-induced ejaculatory failure and anorgasmia [letter]. Am J Psychiatry 1999 Jun; 156(6): 972PubMedGoogle Scholar
  46. 46.
    Brannon GE, Rolland PD. Anorgasmia in a patient with bipolar disorder type I treated with gabapentin. J Clin Psychopharmacol 2000; 20: 379–81PubMedCrossRefGoogle Scholar
  47. 47.
    Rosebush PI, MacQueen GM, Mazurek MF. Catatonia following gabapentin withdrawal [letter]. J Clin Psychopharmacol 1999 Apr; 19(2): 188–9PubMedCrossRefGoogle Scholar
  48. 48.
    Dimond KR, Pande AC, Lamoreaux L, et al. Effect of gabapentin (Neurontin) [corrected] on mood and well-being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 407–17PubMedCrossRefGoogle Scholar
  49. 49.
    Harden CL, Lazar LM, Pick LH, et al. A beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 1999; 40(8): 1129–34PubMedCrossRefGoogle Scholar
  50. 50.
    Magnus L. Nonepileptic uses of gabapentin. Epilepsia 1999; 40Suppl. 6: S66–72PubMedCrossRefGoogle Scholar
  51. 51.
    Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000 Aug; 20(4): 467–71PubMedCrossRefGoogle Scholar
  52. 52.
    Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999 Aug; 19(4): 341–8PubMedCrossRefGoogle Scholar
  53. 53.
    Maurer I, Volz H-P, Sauer H. Gabapentin leads to remission of somatoform pain disorder with major depression. Pharmaco-psychiatry 1999; 32: 255–7Google Scholar
  54. 54.
    Backonja MM, Beydoun A, Edwards KR. Gabapentin monotherapy for the treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. JAMA 1998; 280: 1831–6PubMedCrossRefGoogle Scholar
  55. 55.
    Cutter NC, Scott DD, Johnson J, et al. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000 Feb; 81(2): 164–9PubMedGoogle Scholar
  56. 56.
    Young LT, Robb JC, Patelis-Siotis I, et al. Acute treatment of bipolar depression with gabapentin. Biol Psychiatry 1997; 42: 851–3PubMedCrossRefGoogle Scholar
  57. 57.
    Young LT, Robb JC, Hasey GM, et al. Gabapentin as an adjunctive treatment in bipolar disorder. J Affect Disord 1999; 55: 73–7PubMedCrossRefGoogle Scholar
  58. 58.
    Ghaemi SN, Goodwin FK. Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. J Affect Disord 2001; 65: 167–71PubMedCrossRefGoogle Scholar
  59. 59.
    Soutillo CA, Casuto LS, Keck PE. Gabapentin in the treatment of adolescent mania: a case report. J Child Adolesc Psychopharmacol 1998; 8(1): 81–5CrossRefGoogle Scholar
  60. 60.
    Stanton SP, Keck PE, McElroy SL. Treatment of acute mania with gabapentin [letter]. Am J Psychiatry 1997 Feb; 154(2): 287PubMedGoogle Scholar
  61. 61.
    Bennett J, Goldman WT, Suppes T. Gabapentin for treatment of bipolar and schizoaffective disorders. J Clin Psychopharmacol 1997 Apr; 17(2): 141–2PubMedCrossRefGoogle Scholar
  62. 62.
    Hamrin V, Bailey K. Gabapentin and methylphenidate treatment of a preadolescent with attention deficit hyperactivity disorder and bipolar disorder. J Child Adolesc Psychopharmacol 2001; 11(3): 301–9PubMedCrossRefGoogle Scholar
  63. 63.
    Hatzimanolis J, Lykouras L, Oulis P, et al. Gabapentin as mono-therapy in the treatment of acute mania. Eur Neuropsychopharmacol 1999; 9: 257–8PubMedCrossRefGoogle Scholar
  64. 64.
    Knoll J, Stegman K, Suppes T. Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania. J Affect Disord 1998; 49: 229–33PubMedCrossRefGoogle Scholar
  65. 65.
    Perugi G, Toni C, Ruffolo G, et al. Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. Pharmacopsychiatry 1999; 32: 136–41PubMedCrossRefGoogle Scholar
  66. 66.
    Cabras PL, Hardoy MJ, Hardoy MC, et al. Clinical experience with gabapentin in patients with bipolar and schizoaffective disorder: results of an open-label study. J Clin Psychiatry 1999 Apr; 60(4): 245–8PubMedCrossRefGoogle Scholar
  67. 67.
    Altshuler LL, Keck PE Jr, McElroy SL, et al. Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disord 1999; 1: 61–5PubMedCrossRefGoogle Scholar
  68. 68.
    Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000; 2: 249–55PubMedCrossRefGoogle Scholar
  69. 69.
    Sheldon LJ, Ancill RJ, Holliday SG. Gabapentin in geriatric psychiatry patients [letter]. Can J Psychiatry 1998 May; 43(4): 422–3PubMedGoogle Scholar
  70. 70.
    Ryback RS, Brodsky L, Munasifi F. Gabapentin in bipolar disorder [letter]. J Neuropsychiatry Clin Neurosci 1997; 9(2): 301PubMedGoogle Scholar
  71. 71.
    Schaffer CB, Schaffer LC. Gabapentin in the treatment of bipolar disorder. Am J Psychiatry 1997 Feb; 154(2): 291–2PubMedGoogle Scholar
  72. 72.
    Schaffer CB, Schaffer LC. Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment. J Affect Disord 1999; 55: 237–40PubMedCrossRefGoogle Scholar
  73. 73.
    Gordon A, Price LH. Mood stabilization and weight loss with topiramate. Am J Psychiatry 1999 Jun; 156(6): 968–9PubMedGoogle Scholar
  74. 74.
    Colom F, Vieta E, Benabarre A, et al. Topiramate abuse in a bipolar patient with an eating disorder. J Clin Psychiatry 2001; 62(6): 475–6PubMedCrossRefGoogle Scholar
  75. 75.
    Banta JT, Hoffman K, Budenz DL, et al. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol 2001; 132(1): 112–4PubMedCrossRefGoogle Scholar
  76. 76.
    McElroy SL, Suppes T, Keck Jr PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47: 1025–33PubMedCrossRefGoogle Scholar
  77. 77.
    Normann C, Langosch J, Schaerer LO, et al. Treatment of acute mania with topiramate [letter]. Am J Psychiatry 1999 Dec; 156(12): 2014PubMedGoogle Scholar
  78. 78.
    Pecuch PW, Erfurth A. Topiramate in the treatment of acute mania. J Clin Psychopharmacol 2001; 21(2): 243–4PubMedCrossRefGoogle Scholar
  79. 79.
    Grunze HCR, Normann C, Langosch J, et al. Antimanic efficacy of topiramate in 11 patients in an open trial with on-off-on design. J Clin Psychiatry 2001; 62(6): 464–8PubMedCrossRefGoogle Scholar
  80. 80.
    Calabrese JR, Keck PE, McElroy SL, et al. Pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol 2001; 21(3): 340–2PubMedCrossRefGoogle Scholar
  81. 81.
    Chengappa KNR, Rathore D, Levine J, et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999; 1:42–53PubMedCrossRefGoogle Scholar
  82. 82.
    Letmaier M, Schreinzer D, Wolf R, et al. Topiramate as a mood stabilizer. Int Clin Psychopharmacol 2001; 16: 295–8PubMedCrossRefGoogle Scholar
  83. 83.
    Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998; 50: 245–51PubMedCrossRefGoogle Scholar
  84. 84.
    Emrich HM, Altmann H, Dose M, et al. Therapeutic effects of GABA-ergic drugs in affective disorders: a preliminary report. Pharmacol Biochem Behav 1983; 19: 369–72PubMedCrossRefGoogle Scholar
  85. 85.
    Teitelbaum M. Oxcarbazepine in bipolar disorder. J Am Acad Child Adolesc Psychiatry 2001; 40(9): 993–4PubMedCrossRefGoogle Scholar
  86. 86.
    Schaffer LC, Schaffer CB. Tiagabine and the treatment of refractory bipolar disorder [letter]. Am J Psychiatry 1999 Dec; 156(12): 2014–5PubMedGoogle Scholar
  87. 87.
    Grunze H, Erfurth A, Marcuse A, et al. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999 Nov; 60(11): 759–62PubMedCrossRefGoogle Scholar
  88. 88.
    Kaufman KR. Adjunctive treatment of psychiatric disorders: three cases. Ann Clin Psychiatry 1998 Dec; 10(4): 181–4PubMedGoogle Scholar
  89. 89.
    Elger CE, Bauer J. New antiepileptic drugs in epileptology. Neuropsychobiology 1998; 38: 145–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Mood Disorder Program, Department of Psychiatry and Behavioural NeurosciencesMcMaster UniversityHamiltonCanada
  2. 2.Hamilton Regional Mood Disorder ProgramSt. Joseph’s Healthcare, Centre for Mountain Health ServicesHamiltonCanada

Personalised recommendations